Generic versions of antiretrovirals, or ARVs, that cost a fraction of the price of brand medicines make it possible for MSF to treat 160,000 people living with HIV around the world. Eighty percent of the ARVs we use come from India, and millions of others in developing countries depend on India-made generics as well. But the European Commission has begun directing its trade policies in a way that could stamp out the production of lifesaving generics in India. MSF has launched a global public campaign to tell Europe to back off, and to honor its commitments to global health.
In this edition, listen to reports on current issues affecting access to essential medicines, including a new, easy-to-use treatment for malaria; a court case in India that could prevent millions of people around the world from getting the medicines they need to survive; and on the fight to secure the heat-stable version of a vital AIDS drug in Thailand.